HRT Benefits: What Hormone Therapy Actually Does for You
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 16 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
HRT benefits, clearly explained: hot flashes, GSM, bone, cardiovascular, and mood. What the WHI 18-year follow-up, ELITE, KEEPS, and DOPS actually showed.
The WHI unnecessarily frightened women and left them suffering with very real symptoms, possibly preventing them from taking a life-changing, even life-prolonging treatment. HRT can have beneficial impacts on bones, brains, and heart — and many common fears around hormone therapy are not supported by the latest scientific evidence.
If you’re researching HRT benefits, you’re almost certainly working through two competing stories — the one your mother heard in 2002 about a study that “showed HRT causes cancer,” and the one you’re reading now from menopause specialists who say the original interpretation was wrong, that hormone therapy is safe and effective for most women under 60, and that not using it has its own costs. The honest answer is closer to the second story than the first, with important caveats.
This guide walks through what hormone therapy actually does — symptom by symptom, system by system — based on the position statements and major trials that frame current practice, including the WHI 18-year follow-up, KEEPS, ELITE, and DOPS. It is not a “should you take HRT” decision tool; that decision belongs to you and a clinician who knows your history. It is a clear-eyed summary of what the benefits actually are.
Key takeaways
For appropriately selected women under 60 or within 10 years of their final menstrual period, hormone therapy is the most effective treatment for moderate-to-severe vasomotor symptoms and meaningfully reduces several long-term health risks — per the Menopause Society’s 2022 Hormone Therapy Position Statement.
The “timing hypothesis,” supported by KEEPS, ELITE, and the WHI 18-year follow-up, holds that the benefit-risk balance of hormone therapy depends heavily on when it’s started — earlier in the transition is more favorable than later.
HRT benefits include substantial reduction in hot flashes and night sweats (typically 70–90 percent), treatment of genitourinary syndrome of menopause, prevention of osteoporotic fracture, and, for women starting near menopause, a likely reduction in cardiovascular events confirmed in DOPS.
HRT is not appropriate for everyone — contraindications include a history of estrogen-sensitive breast cancer, certain cardiovascular events, active liver disease, and unexplained vaginal bleeding.
The decision to use hormone therapy should be made with a clinician who knows your full history. The phrase “lowest dose for shortest duration” is outdated; current guidance individualizes both.
The short answer on HRT benefits
For most women under 60 or within 10 years of their final menstrual period, hormone therapy provides the largest reduction in vasomotor symptoms of any available treatment, restores genitourinary tissue function, prevents bone loss, and — based on the DOPS trial and WHI 18-year follow-up — is likely associated with reduced cardiovascular and all-cause mortality when started near the time of menopause.
That is a meaningfully different summary than the one circulated in the years immediately after the original WHI publication in 2002. The reinterpretation reflects nearly 20 years of follow-up data and several large randomized trials that specifically tested the timing hypothesis: that hormone therapy started early in the menopause transition has a different risk-benefit profile than the same therapy started a decade or more later.
Why the older HRT story was incomplete
The 2002 publication of the Women’s Health Initiative (WHI) trial — Rossouw and colleagues in JAMA — changed practice overnight. The trial was stopped early because of an increase in breast cancer and cardiovascular events in the combined estrogen-progestin arm.
What didn’t get communicated as clearly: the average age of WHI participants was 63, more than a decade past the typical age of menopause. The trial was answering a different question than the one most women in their early 50s with symptoms were asking. It was a primary-prevention trial in older women, not a symptom-management trial in younger women.
Subsequent analyses and trials made this clear. The Manson 18-year follow-up of WHI, published in JAMA in 2017, showed no statistically significant increase in all-cause mortality with hormone therapy. Subgroup analyses suggested favorable mortality findings in women who started hormone therapy in their 50s, consistent with the timing hypothesis. The DOPS Danish Osteoporosis Prevention Study, in which women started hormone therapy near the time of menopause, found a reduction in the composite endpoint of mortality, heart failure, and myocardial infarction at 10-year follow-up.
KEEPS (the Kronos Early Estrogen Prevention Study, Harman 2014) and the ELITE Trial (Hodis 2016, NEJM) provided the most direct tests of the timing hypothesis using imaging endpoints. ELITE showed that estrogen started within 6 years of menopause slowed the progression of carotid intima-media thickness — an early atherosclerosis marker — while estrogen started 10+ years out did not. KEEPS likewise found no adverse cardiovascular effects of hormone therapy started early in the transition.
The current synthesis, captured in both the Menopause Society 2022 position statement and NICE Guideline NG23 (updated November 2024), is that hormone therapy is appropriate first-line treatment for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of their final period, with the risk-benefit calculus highly favorable in that window.
HRT benefits for hot flashes and night sweats
HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.
Vasomotor symptom reduction is the most consistent and largest benefit of hormone therapy. At standard systemic doses, hormone therapy typically reduces hot flash frequency by 70 to 90 percent — substantially more than any non-hormonal option, including the SSRIs/SNRIs, gabapentin, and fezolinetant covered in the Menopause Society’s 2023 Nonhormone Therapy Position Statement.
For night sweats specifically, the sleep impact is meaningful. Reducing nocturnal vasomotor episodes translates directly into less fragmented sleep, which carries its own downstream benefits for mood, energy, and cognition. The fuller picture connects to our explainers on menopause night sweats and menopause insomnia.
This is why for many women with moderate-to-severe VMS, hormone therapy is the right starting point rather than a fallback after non-hormonal options have been tried.
HRT benefits for genitourinary syndrome of menopause
Genitourinary syndrome of menopause (GSM) — vaginal dryness, painful sex, urinary urgency, recurrent UTIs — follows a different trajectory than hot flashes. Rather than improving over time, GSM typically worsens with sustained estrogen deficiency, per the Menopause Society’s 2020 GSM position statement.
For GSM, two categories of estrogen therapy are relevant:
Systemic hormone therapy (oral, transdermal, transvaginal ring at systemic doses) provides genitourinary benefit alongside its other effects.
Low-dose vaginal estrogen (cream, tablet, ring) treats GSM specifically with minimal systemic absorption. It does not require a progestogen in most cases and has a favorable safety profile even in many women for whom systemic estrogen would be contraindicated.
The reassurance on vaginal estrogen safety is grounded in data from the WHI Observational Study analyzed by Crandall and colleagues in Menopause in 2018, which found no increased risk of cardiovascular events, breast cancer, or other major outcomes in users of low-dose vaginal estrogen compared with non-users.
The detail matters because GSM affects roughly half of postmenopausal women and is one of the symptoms that genuinely persists without treatment. Our explainer on is vaginal estrogen safe walks through the evidence in depth.
HRT benefits for bone health
Postmenopausal estrogen deficiency drives accelerated bone loss in the first 5 to 7 years after the final period, raising the long-term risk of osteoporotic fracture. Hormone therapy prevents this bone loss.
In the WHI, the estrogen-progestin arm showed a statistically significant reduction in hip and clinical vertebral fractures, documented in the Cauley 2003 bone substudy. The DOPS trial similarly showed reduced fracture risk in women who started hormone therapy near menopause.
Bone-preserving effects of estrogen are dose-dependent and require ongoing use to maintain. When hormone therapy is stopped, bone loss resumes at a rate similar to what would have occurred had treatment never been started. For women at meaningful fracture risk for whom hormone therapy isn’t continued, other bone-active treatments — bisphosphonates, denosumab, others — are options to discuss with a clinician.
For most women without specific osteoporosis risk factors, the bone benefit is a useful side benefit of hormone therapy used for VMS rather than the primary indication.
HRT benefits for cardiovascular health (with the timing caveat)
Vaginal hormones should be like giving out blood pressure medication to your patients — evidence-based, effective, and offered proactively. Women over 45 should be offered these therapies and understand how safe and effective they are.
This is the area where the older interpretation of WHI was most misleading and the newer trial data are most clarifying.
The timing hypothesis holds that estrogen started near the time of menopause — when vascular endothelium is healthier and atherosclerosis is less advanced — has different effects than the same therapy started a decade or more later, after subclinical atherosclerosis has progressed.
The ELITE Trial was the most direct test: oral estradiol slowed carotid intima-media thickness progression in women within 6 years of menopause but had no effect in women 10+ years out. KEEPS, using a different design with both oral and transdermal estrogen, found no adverse cardiovascular effects in early-postmenopausal women. DOPS, with longer follow-up, found a reduction in the composite of mortality, heart failure, and MI in women who began hormone therapy at the average age of 49.
The synthesis: hormone therapy started in the early postmenopausal window does not appear to increase cardiovascular risk and may reduce it. Hormone therapy started in older women with established subclinical atherosclerosis can increase risk. This is why current guidance specifies the under-60 or within-10-years window.
The AHA Scientific Statement on Menopause Transition and Cardiovascular Disease Risk frames the menopause transition itself as a cardiometabolic inflection point worth attention regardless of whether hormone therapy is used. Lipid changes, central adiposity, vascular stiffness, and metabolic syndrome risk all shift around the transition.
HRT benefits for mood and cognition (mixed)
The data on hormone therapy and mood are more nuanced. Hormone therapy is not a primary treatment for depression. However, for women whose mood symptoms appear or worsen during the perimenopausal transition — the window of greatest mood vulnerability per Bromberger and colleagues’ SWAN analysis — hormone therapy can help, particularly when vasomotor symptoms and sleep loss are contributing.
For cognition, the picture is more cautious. The Women’s Health Initiative Memory Study (WHIMS) reported an increased risk of dementia and cognitive decline in women started on hormone therapy at age 65 or older — a result widely interpreted as another timing-hypothesis signal rather than evidence against hormone therapy in younger women. KEEPS-Cog, the cognitive arm of KEEPS, found no cognitive harm or benefit from hormone therapy started in early postmenopause.
Current guidance does not recommend hormone therapy for the primary prevention of cognitive decline or dementia at any age. It does not contraindicate hormone therapy for symptom relief in women whose cognitive complaints during the transition are part of a broader symptom cluster.
What HRT does not do
A clear-eyed framing also includes the things hormone therapy is not for:
It is not a “fix” for weight gain. Body composition changes during the transition reflect age and hormonal influences both; hormone therapy has modest effects at best.
It does not eliminate every menopause symptom for every woman. Some women still have residual symptoms on therapy and need adjustments.
It is not primary prevention for dementia.
It is not a longevity intervention as such. The mortality findings from WHI’s 18-year follow-up and DOPS are reassuring but specific to the women and circumstances studied.
Who should not use HRT
Hormone therapy is contraindicated or requires careful individualization in several situations:
History of estrogen-sensitive breast cancer
Personal history of venous thromboembolism, stroke, or recent myocardial infarction
Active liver disease
Unexplained vaginal bleeding
Known or suspected pregnancy
Each of these has nuance — for example, women with breast cancer history may still be candidates for vaginal estrogen at low dose, depending on their oncology team’s input. The point is that the decision is individualized.
For women with surgical menopause from oophorectomy under age 45, the guidance generally favors hormone therapy until at least the average age of natural menopause, given the long horizon of estrogen deficiency. Our guide on surgical menopause covers this in detail.
What this means for you
Three points worth taking forward:
The under-60 / within-10-years window matters. The risk-benefit calculus is substantially more favorable in this window than later, per the timing hypothesis and the body of trial evidence.
“Lowest dose for shortest duration” is outdated framing. Current guidance individualizes both based on your symptoms, history, and response.
Vaginal estrogen is a separate decision from systemic hormone therapy and has a favorable safety profile even for many women who can’t use systemic therapy.
The right decision is the one you make with a clinician who knows your full history and current evidence. The Menopause Society 2022 statement and NICE NG23 are the two references most often used to frame that conversation.
When to talk to your doctor
Reasonable triggers for a conversation about hormone therapy:
Moderate-to-severe hot flashes or night sweats interfering with sleep, work, or daily function
Vaginal dryness, painful sex, or recurrent UTIs you’ve been told to “just live with”
Bone density concerns or a strong family history of osteoporosis
Premature ovarian insufficiency or surgical menopause under age 45
A previous “no” from a clinician that didn’t engage with current evidence
A desire to understand your individual risk-benefit balance rather than rely on general statements
If you’d like to prepare for the conversation, our guide on talking to your doctor about menopause walks through what to bring, what to ask, and how to advocate for yourself if you feel dismissed.
Frequently asked questions
What are the main HRT benefits?
The largest documented benefits are substantial reduction in vasomotor symptoms (typically 70–90 percent), treatment of genitourinary syndrome of menopause, prevention of bone loss and osteoporotic fracture, and — for women starting near the time of menopause — likely cardiovascular benefit per DOPS and ELITE data.
Is HRT safe?
For most women under 60 or within 10 years of their final period without specific contraindications, current guidance from the Menopause Society and NICE characterizes hormone therapy as safe and appropriate first-line treatment for moderate-to-severe symptoms. Risk-benefit balance shifts unfavorably when therapy is started more than a decade out from menopause.
Does HRT cause breast cancer?
The WHI estrogen-plus-progestin arm showed a small absolute increase in breast cancer diagnoses; the estrogen-alone arm in women without a uterus did not. The magnitude in trial terms was small. The decision is individualized based on personal history, family history, and time since menopause. Women with a history of estrogen-sensitive breast cancer generally do not use systemic hormone therapy.
What is the timing hypothesis?
The timing hypothesis holds that hormone therapy started early in the menopause transition has a more favorable cardiovascular profile than the same therapy started in older women with established subclinical atherosclerosis. ELITE, KEEPS, and the WHI 18-year follow-up are the major data sources.
Is transdermal HRT safer than oral?
Transdermal estrogen — patches, gels, sprays — bypasses the liver’s first-pass metabolism and is associated with lower risk of venous thromboembolism than oral estrogen. For many women, particularly those with VTE risk factors, transdermal is the preferred route.
Can I take HRT long-term?
There’s no fixed duration limit in current guidance. The 2022 Menopause Society statement explicitly moved away from the “lowest dose, shortest duration” framing. Decisions about ongoing use are individualized and revisited periodically with your clinician based on your symptoms, risk profile, and current evidence.
Sources
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938. (WHI 18-year follow-up.)
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. NEJM. 2016;374(13):1221-1231. (ELITE Trial.)
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249-260. (KEEPS.)
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. (DOPS.)
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20.
The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement. Menopause. 2020;27(9):976-992.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Hormone therapy — including systemic estrogen, estrogen-progestogen combinations, and low-dose vaginal estrogen — requires evaluation and prescription by a clinician. It is not appropriate for everyone, has specific contraindications including a history of estrogen-sensitive cancers and certain cardiovascular events, and decisions about duration of use should be revisited periodically with your clinician. Do not start, stop, or change hormone therapy without speaking to your clinician.
